Navigation Links
Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
Date:5/7/2008

arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.

"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of pharmaceutical research, product development including, but not limited to the successful development of JUVISTA(R) (Human TGF(beta)3) and velaglucerase alfa (GA-GCB); manufacturing and commercialization including, but not limited to, the establishment in the market of VYVANSE(TM) (lisdexamfetamine dimesylate) (Attention Deficit and Hyperactivity Disorder ("ADHD")); the impact of competitive products, including, but not limited to, the impact of those on Shire's ADHD franchise; patents, including but not limited to, legal challenges relating to Shire's ADHD franchise; government regulation and approval, including but not limited to the expected product approval date of INTUNIV(TM) (guanfacine extended release) (ADHD); Shire's ability to secure new products for commercialization and/or development; and other risks and uncertainties detailed from time to time in Shire plc's filings with the Securities and Exchange Commission, including Shire plc's Annual Report on Form 10-
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmacopeia Announces Upcoming Late-Breaker Presentation of Phase 2a Results for Its First-in-Class Investigational DARA Compound, PS433540
2. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
3. Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
4. FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
5. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
6. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
7. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
8. SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients
9. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
10. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
11. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2008)...iland, May 9 /PRNewswire-USNewswire/ -- An emergen...Protection of Animals (WSPA),is on stand-by in Tha...yanmar to assess and then relieve the suffering of...on for food and their livelihoods., WSPA is rec...,Organization of the United Nations (FAO) while pr...
(Date:5/9/2008)...ay 9 /- Ardea Biosciences, ...scovery and development of,small- molecule therape...atory diseases, including gout, today announced th...sident, Finance and Operations and Chief,Financial...om our board of,directors shortly thereafter. The ...
(Date:5/8/2008)... /- Globus Medical, Inc., the largest... world and a recognized,leader in motion preservat...enrollment in its SECURE(R)-C Cervical Artificial ... to mimic the normal motion of the spine in,order ...native to fusion in,the treatment of symptomatic c...
(Date:5/8/2008)...ll., May 8 /- Siemens Healt...dings (LabCorp(R)) today announced,that they have ...e,possibilities to co-develop new clinical diagnos...etabolic syndrome, oncology and diabetes. Under th...eloping new tests that,could make the biggest impa...
Breaking Medicine Technology:Animals That Cyclone Survivors Depend on Need Help Now 2Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 2Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 3Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 4Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 5Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 6Globus Medical Completes Enrollment Of SECURE(R)-C Cervical Artificial Disc Clinical Trial 2Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 2Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 3Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 4Canola Oil Can Help Americans Meet Dietary Fat Recommendations 2898 1Canola Oil Can Help Americans Meet Dietary Fat Recommendations 2898 2Brown researchers make major signal transduction discovery 2897 1Brown researchers make major signal transduction discovery 2897 2Diet com Enters Strategic Collaboration To Support Microsoft HealthVault 2894 1Diet com Enters Strategic Collaboration To Support Microsoft HealthVault 2894 2Genta to Present at Bio Investor Forum 2007 Conference 2889 1Genta to Present at Bio Investor Forum 2007 Conference 2889 2Genta to Present at Bio Investor Forum 2007 Conference 2889 3
...nt duloxetine, at,a once-daily dose of 60 mg, sign...symptoms associated with depression in a new,eigh...ents with at,least moderate pain and major depress...European Congress of Psychiatry (AEP),in Madrid, S...ommonly referred to as,serotonin and norepinephrin...
...rstCall/ --,Alfacell Corporation,s ONCONASE (ranpi...oad in antibody conjugates for cancer therapy,acc...erapeutic,Antibodies. , In a chapter of the text t...marizes preclinical research indicating that the,s...umber of tumor,models, including non-Hodgkin,s lym...
Other Medicine Technology:In New Study, Duloxetine Reduced Non-specific Pain and Emotional,Symptoms Associated with Depression 2In New Study, Duloxetine Reduced Non-specific Pain and Emotional,Symptoms Associated with Depression 3In New Study, Duloxetine Reduced Non-specific Pain and Emotional,Symptoms Associated with Depression 4In New Study, Duloxetine Reduced Non-specific Pain and Emotional,Symptoms Associated with Depression 5In New Study, Duloxetine Reduced Non-specific Pain and Emotional,Symptoms Associated with Depression 6Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 2Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 3Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 4
(Date:5/12/2008)...ire-FirstCall/ -- (Nasdaq: WHRT, TSX:,WHT) World H...") announced,that the Toronto Stock Exchange ("TSX...g the eligibility for continued listing on the TSX... 709 and 710(a) of the TSX Company,Manual. This re...and,operating results, more specifically whether t...
(Date:5/12/2008)...rstCall/ -- Allied Healthcare Products,Inc. (Nasd... the third,quarter ending March 31 fell 64 percent...are, to about $100,000 in the current quarter, or ...creased by about $240,000 compared to the,third qu...and labor costs,this fiscal year eroded margins an...
(Date:5/12/2008)...Newswire-FirstCall/ -- China Yingxia,International... or "the,Company"), a leading provider in the nutr...ufacture and distribution of organic nutritional f...cts in the People,s Republic,of China ("PRC"), ann...iday, May 16, 2008, at 10:00 a.m. EDT, to discuss ...
(Date:5/12/2008)...RME TSX: COM, VANCOUVER, May 12 /PRNewswire-First... COM) today announced that it will report financia...ernoon of Tuesday, May 13,2008. Cardiome will hol...ern (1:30pm Pacific) on that day to discuss the re...l 416-641-6117 or,866-299-6655. There will be a se...
Breaking Medicine News(10 mins):Health News:WorldHeart Notified of TSX Delisting Review 2Health News:Allied Healthcare Net Falls on Manufacturing Delays 2Health News:Allied Healthcare Net Falls on Manufacturing Delays 3Health News:Allied Healthcare Net Falls on Manufacturing Delays 4Health News:Allied Healthcare Net Falls on Manufacturing Delays 5Health News:China Yingxia International, Inc. Announces Conference Call to Discuss First Quarter 2008 Results 2Health News:Cardiome To Release 2008 First Quarter Results 2Health News:Cardiome To Release 2008 First Quarter Results 3Health News:Cardiome To Release 2008 First Quarter Results 4
...that is used in hard plastics that are commonly us...g breast cancer,// according to a new study. Rese... of California report their findings in the recent...esearchers were able to prove that the chemical, b...
... only when they affect only the diseased organs or...esearchers attempted to direct microcapsules into ...elp of a laser impulse. They have succeeded in rel...l. They did this by putting the substance into a s...
...rtant information about how water reacts with the ... mutation that has eluded researchers for decades....n of the Journal of the American Chemical Society,...y have reported uncovering an important step in DN...
...f Health is using fines paid by speeding motorist ...er-one cause nationwide is motor vehicle// acciden...ed in 1998 uses these fines to fund research, and ...hester Medical Center are among the programs funde...
Other Medicine News:Health News:Microcapsules target cancer cells 2Health News:Microcapsules target cancer cells 3Health News:Elusive Step In DNA Mutation Uncovered By Researchers 2Health News:Elusive Step In DNA Mutation Uncovered By Researchers 3Health News:Elusive Step In DNA Mutation Uncovered By Researchers 4Health News:Fines Paid By Speeding Motorists Used in Funding Spinal Cord Injury Research 2
Bird and Cronin, Inc. is a leading manufacturer of Patient Footwear, Orthopedic Softgoods, and Specialty Patient Care Products. Our products are of the highest quality and available in the USA and In
Bird and Cronin, Inc. is a leading manufacturer of Patient Footwear, Orthopedic Softgoods, and Specialty Patient Care Products. Our products are of the highest quality and available in the USA and In
...s specifically designed to treat Achilles tendonit... aircells located under the foot arch and in back ...sion with every step to help reduce swelling and e...ight neoprene fabric and is simple to apply just ...
... choice to treat arthritic pain, carpal tunnel syn... cast removal. The durable canvas glove with adju... and compression to the wrist to help relieve swel...t prevents painful wrist flexion, and holds the wr...
Medicine Products: